Kelly W Westbrook

Assistant Professor of Medicine

Medicine, Medical Oncology

kelly.westbrook@duke.edu

3459, 447 Mudd Building, Durham, NC 27710

3459, 447 Mudd Building, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education
2. Training & Certifications

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition
1. In the News

Professional Activities

Embed Profile Data

Embed Profile Data

Selected Grants

AFT-05/PALLAS

Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2016 - 2025

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive

Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2017 - 2025

TBCRC45: AVIATOR: A Phase II Study Of Trastuzumab, Vinorelbine, and Avelumab ± PF-05082566 (4-1BB/CD137 Agonist) in HER2+ MBC

Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2019 - 2024

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer

Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2019 - 2024

Addressing Sexual Concerns in Breast Cancer Survivors: RCT of a Novel Couple-Based Intervention

ResearchCo Investigator · Awarded by Fox Chase Cancer Center · 2018 - 2024

Oncothyreon ONT 380-206

ResearchPrincipal Investigator · Awarded by Cascadian Therapeutics Inc. · 2016 - 2023

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor

ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2023

Couple Communication in Cancer: A Multi-method Examination

ResearchCo Investigator · Awarded by Arizona State University · 2016 - 2022

Optimizing Delivery of a Behavioral Cancer Pain Intervention Using a SMART

ResearchClinical Associate · Awarded by National Institutes of Health · 2016 - 2022

Reimagine End of Life: An Online, Personalized Coping and Decision Aid for Metastatic Breast Cancer Patients and Providers

ResearchCo Investigator · Awarded by Pfizer, Inc. · 2016 - 2018

A randomized doubleblind, placebo controlled study of ribociclib in combination w/fulvestrant for the treatment of postmenopausal women w/hormone receptor positive, HER2-, advanced breast cancer who have received no or only 1line of prior endo treatm

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2017